IL95473A - A drug preparation for the treatment of premature ejaculation using sertraline - Google Patents
A drug preparation for the treatment of premature ejaculation using sertralineInfo
- Publication number
- IL95473A IL95473A IL9547390A IL9547390A IL95473A IL 95473 A IL95473 A IL 95473A IL 9547390 A IL9547390 A IL 9547390A IL 9547390 A IL9547390 A IL 9547390A IL 95473 A IL95473 A IL 95473A
- Authority
- IL
- Israel
- Prior art keywords
- sertraline
- premature ejaculation
- pharmaceutical composition
- pharmaceutically acceptable
- treating premature
- Prior art date
Links
- 206010036596 premature ejaculation Diseases 0.000 title claims abstract description 7
- 229960002073 sertraline Drugs 0.000 title abstract description 15
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- -1 hydrochloric Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229960003660 sertraline hydrochloride Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical class C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/400,417 US4940731A (en) | 1989-08-30 | 1989-08-30 | Method of treating premature ejaculation using sertraline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL95473A true IL95473A (en) | 1995-08-31 |
Family
ID=23583530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9547390A IL95473A (en) | 1989-08-30 | 1990-08-23 | A drug preparation for the treatment of premature ejaculation using sertraline |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4940731A (de) |
| EP (1) | EP0415613B1 (de) |
| JP (1) | JPH0393718A (de) |
| KR (1) | KR910004187A (de) |
| AT (1) | ATE110958T1 (de) |
| AU (1) | AU609664B1 (de) |
| CA (1) | CA2024188C (de) |
| CY (1) | CY1973A (de) |
| DE (1) | DE69012261T2 (de) |
| DK (1) | DK0415613T3 (de) |
| HK (1) | HK219196A (de) |
| HU (1) | HU213474B (de) |
| IE (1) | IE63470B1 (de) |
| IL (1) | IL95473A (de) |
| MY (1) | MY106938A (de) |
| NZ (1) | NZ235101A (de) |
| PH (1) | PH26998A (de) |
| PT (1) | PT95117B (de) |
| ZA (1) | ZA906883B (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0148511B1 (ko) * | 1993-09-14 | 1998-11-02 | 최형기 | 성신경과민증 예방 및 치료용 의약조성물 |
| US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
| US20030133974A1 (en) * | 1997-07-01 | 2003-07-17 | Curatolo William John | Encapsulated solution dosage forms of sertraline |
| IL133080A0 (en) | 1997-07-01 | 2001-03-19 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6228864B1 (en) | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
| US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
| US6037360A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
| UA72743C2 (en) * | 1998-10-13 | 2005-04-15 | Pfizer Prod Inc | Essentially nonaqueous liquid pharmaceutical concentrate composition containing sertraline, method of using this concentrate, method for treatment |
| IL132500A0 (en) | 1998-10-29 | 2001-03-19 | Pfizer Prod Inc | Stereoselective microbial reduction of a racemic tetralone |
| ES2245639T3 (es) * | 1999-03-01 | 2006-01-16 | Pfizer Inc. | Compuestos 1,2,3,4-tetrahidro-1-naftalenamina utiles en terapia. |
| US6245782B1 (en) | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| EP1671628B1 (de) * | 1999-09-03 | 2012-10-03 | APBI Holdings, LLC | Selektive Serotonin-Aufnahme Inhibitoren mit schnellem Wirkungseintritt zur Behandlung von sexueller Dysfunktionen |
| WO2001047498A2 (en) | 1999-12-23 | 2001-07-05 | Pfizer Products Inc. | Hydrogel-driven layered drug dosage form comprising sertraline |
| GB0007884D0 (en) * | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
| US6448293B1 (en) | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| CN1091096C (zh) * | 2000-09-15 | 2002-09-18 | 哈尔滨健迪医药科技开发有限公司 | 舍曲林柠檬酸盐及其用于治疗哺乳动物早泄的用途 |
| US6495154B1 (en) | 2000-11-21 | 2002-12-17 | Vivus Inc. | On demand administration of clomipramine and salts thereof to treat premature ejaculation |
| NZ528935A (en) | 2001-03-16 | 2004-10-29 | Dmi Biosciences Inc | Method of delaying ejaculation |
| US20040131672A1 (en) * | 2003-01-07 | 2004-07-08 | Nilobon Podhipleux | Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties |
| AU2003903597A0 (en) * | 2003-07-11 | 2003-07-24 | Jakov Vaisman | Treatment of premature ejaculation |
| EP1737473A4 (de) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | Lithium-kombinationen und relevante verwendungen |
| BRPI0509592A (pt) * | 2004-05-06 | 2007-09-25 | Cydex Inc | formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila |
| EP1969117A4 (de) * | 2005-12-13 | 2008-12-17 | Trinity Lab Inc | Verfahren zur behandlung einer vorzeitigen ejakulation beim menschen |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| US20090005319A1 (en) * | 2007-07-01 | 2009-01-01 | Barone Jr Frank V | Topical compositions for delaying ejaculation and methods of using the same |
| US9272671B2 (en) | 2013-06-28 | 2016-03-01 | Faurecia Interior Systems, Inc. | Display screen arrangement and method of assembly |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029731A (en) * | 1974-11-06 | 1977-06-14 | Pfizer Inc. | Aminophenyltetralin compounds |
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4507323A (en) * | 1984-07-25 | 1985-03-26 | Burroughs Wellcome Co. | Treatment of psychosexual dysfunctions |
| US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
-
1989
- 1989-08-30 US US07/400,417 patent/US4940731A/en not_active Expired - Lifetime
-
1990
- 1990-08-17 DK DK90309063.7T patent/DK0415613T3/da active
- 1990-08-17 DE DE69012261T patent/DE69012261T2/de not_active Expired - Fee Related
- 1990-08-17 EP EP90309063A patent/EP0415613B1/de not_active Expired - Lifetime
- 1990-08-17 AT AT90309063T patent/ATE110958T1/de not_active IP Right Cessation
- 1990-08-21 PH PH41056A patent/PH26998A/en unknown
- 1990-08-23 IL IL9547390A patent/IL95473A/en not_active IP Right Cessation
- 1990-08-28 CA CA002024188A patent/CA2024188C/en not_active Expired - Fee Related
- 1990-08-28 PT PT95117A patent/PT95117B/pt not_active IP Right Cessation
- 1990-08-28 MY MYPI90001472A patent/MY106938A/en unknown
- 1990-08-29 KR KR1019900013368A patent/KR910004187A/ko not_active Ceased
- 1990-08-29 HU HU905682A patent/HU213474B/hu not_active IP Right Cessation
- 1990-08-29 AU AU61944/90A patent/AU609664B1/en not_active Ceased
- 1990-08-29 IE IE312390A patent/IE63470B1/en not_active IP Right Cessation
- 1990-08-29 ZA ZA906883A patent/ZA906883B/xx unknown
- 1990-08-30 JP JP2229545A patent/JPH0393718A/ja active Pending
- 1990-08-30 NZ NZ235101A patent/NZ235101A/en unknown
-
1996
- 1996-12-24 HK HK219196A patent/HK219196A/en not_active IP Right Cessation
-
1997
- 1997-09-05 CY CY197397A patent/CY1973A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU905682D0 (en) | 1991-03-28 |
| HK219196A (en) | 1997-01-03 |
| DE69012261T2 (de) | 1995-01-12 |
| EP0415613A3 (en) | 1992-02-26 |
| NZ235101A (en) | 1997-01-29 |
| HUT58512A (en) | 1992-03-30 |
| HU213474B (en) | 1997-06-30 |
| CA2024188C (en) | 1994-11-08 |
| DE69012261D1 (de) | 1994-10-13 |
| EP0415613A2 (de) | 1991-03-06 |
| KR910004187A (ko) | 1991-03-28 |
| DK0415613T3 (da) | 1994-10-10 |
| PT95117B (pt) | 1997-05-28 |
| EP0415613B1 (de) | 1994-09-07 |
| ZA906883B (en) | 1992-04-29 |
| US4940731A (en) | 1990-07-10 |
| CA2024188A1 (en) | 1991-03-01 |
| PT95117A (pt) | 1991-05-22 |
| ATE110958T1 (de) | 1994-09-15 |
| AU609664B1 (en) | 1991-05-02 |
| IE63470B1 (en) | 1995-04-19 |
| IE903123A1 (en) | 1991-03-13 |
| JPH0393718A (ja) | 1991-04-18 |
| MY106938A (en) | 1995-08-30 |
| PH26998A (en) | 1993-02-01 |
| CY1973A (en) | 1997-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4940731A (en) | Method of treating premature ejaculation using sertraline | |
| EP0429189B1 (de) | Verwendung von Sertraline zur Herstellung eines Arzneimittels zur Behandlung von obsessiv-kompulsiven Erkrankungen | |
| IE83452B1 (en) | Use of sertraline for the manufacture of a medicament for treating obsessive-compulsive disorders | |
| US5130338A (en) | Method of treating chemical dependencies using sertraline | |
| CA2024181C (en) | Method of treating chemical dependencies using sertraline | |
| AU721967B2 (en) | The use of sertraline to treat post myocardial infarction patients | |
| IE83776B1 (en) | Use of sertraline to treat post traumatic stress disorder | |
| IE84561B1 (en) | Use of sertraline to treat social phobia | |
| MXPA96002793A (en) | Use of sertraline to treat patients after an infection of miocar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |